Search: id:"swepub:oai:lup.lub.lu.se:fc9858a3-cb51-4661-9e5a-6bcafc3ea94e" >
The current role of...
The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial
-
- Willenheimer, Ronnie (author)
- Lund University,Lunds universitet,Kardiologiska klinikens forskargrupp,Forskargrupper vid Lunds universitet,Cardiology Research Group,Lund University Research Groups
-
(creator_code:org_t)
- 2009-02-12
- 2009
- English.
-
In: European Heart Journal Supplements. - : Oxford University Press (OUP). - 1520-765X. ; 11:A, s. 15-20
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://academic.oup...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Beta-blockers (bisoprolol, metoprolol succinate, carvedilol, and to some extent nebivolol), given on top of angiotensin-converting enzyme (ACE) inhibitors, improve survival and reduce morbidity in symptomatic stable chronic heart failure (CHF). Early beta-blockade may help to improve survival and especially prevent sudden death, but the usual practice of starting the ACE inhibitor first may lead to undertreatment with beta-blockers. The Cardiac Insufficiency Bisoprolol (CIBIS) III trial examined the optimum order of initiating CHF treatment in 1010 patients ( :65 years), with stable, mildly, or moderately symptomatic, systolic CHF. Patients were randomized to initial monotherapy with bisoprolol for up to 6 months, followed by the addition of enalapril, or the opposite sequence. Mean follow-up was 1.2 years. The bisoprolol-first and enalapril-first strategies showed similar efficacy for the combined primary endpoint of mortality or all-cause hospitalization, and similar safety. Compared with the enalapril-first strategy, the bisoprolol-first strategy significantly reduced sudden death during the first year on treatment by 46% (P < 0.05). Patients who achieved higher doses of the study drugs (particularly bisoprolol) had substantially and independently lower mortality and hospitalization risks. Thus, CIBIS III supports a free choice between bisoprolol and enalapril as initial therapy for stable, mild-to-moderate, systolic CHF, and suggests that early beta-blockade reduces the risk of sudden death in the first year.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- enzyme inhibitor
- Sequence of drug initiation
- Angiotensin-converting
- Beta-blocker
- Chronic heart failure
- Therapy
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database